Similar articles

• Intravenous milrinone: therapeutic responses in heart failure.

  Braunwald E. Braunwald E. Am Heart J. 1991 Jun;121(6 Pt 2):1937-8. doi: 10.1016/0002-8703(91)90827-5. Am Heart J. 1991. PMID: 2035423 No abstract available.
• Intravenous milrinone in patients with severe congestive cardiac failure awaiting heart transplantation.

  Skoyles JR, Sherry KM, Price C. Skoyles JR, et al. J Cardiothorac Vasc Anesth. 1992 Apr;6(2):222-5. doi: 10.1016/1053-0770(92)90205-l. J Cardiothorac Vasc Anesth. 1992. PMID: 1568013 No abstract available.
• Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.

  Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, et al. Packer M, et al. N Engl J Med. 1991 Nov 21;325(21):1468-75. doi: 10.1056/NEJM199111213252103. N Engl J Med. 1991. PMID: 1944425 Clinical Trial.
• Phosphodiesterase inhibitors. Its role in heart failure therapy.

  Kohn IJ, Ribeiro LG. Kohn IJ, et al. Arq Bras Cardiol. 1990 Jun;54(6):361-5. Arq Bras Cardiol. 1990. PMID: 1963059 Review. No abstract available.
• Therapeutic achievements of phosphodiesterase inhibitors and the future.

  Jewitt DE. Jewitt DE. Eur Heart J. 1989 Aug;10 Suppl C:53-9. doi: 10.1093/eurheartj/10.suppl_c.53. Eur Heart J. 1989. PMID: 2680498 Review.